Is Anthem Bioscienc overvalued or undervalued?

As of 29 August 2025, the valuation grade for Anthem Bioscienc has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE ratio of 90.82, a Price to Book Value of 18.59, and an EV to EBITDA ratio of 65.82. These ratios are considerably higher than its peers, such as Sun Pharma with a PE of 33.34 and Divi's Lab at 70.28, both of which are categorized as expensive or very expensive.
In comparison to other companies in the pharmaceuticals and biotechnology sector, Anthem Bioscienc's high valuation metrics suggest that investors are paying a premium for its stock. The PEG ratio is notably at 0.00, which raises concerns about growth expectations not being met. While the stock has shown a positive return of 4.51% over the past month compared to a decline in the Sensex, the overall valuation still points to an overvaluation scenario.